BRAF and melanoma: Based on the observation that the CDK4/6 pathway is frequently altered in melanoma, CDK4/6 inhibitors have emerged as potential agents for treating patients with NRAS-mutant and BRAF-wild-type tumors that have not lost the tumor suppressor retinoblastoma protein (pRb) (10, 11).